Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Becton, Dickinson and Company    BDX

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Becton Dickinson and : BD Launches Enhanced Antimicrobial Stewardship Analytics Capabilities

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/21/2019 | 09:06am EST

New antimicrobial stewardship technology will be demonstrated at ASHP 2019 Midyear Meeting

FRANKLIN LAKES, N.J., Nov. 21, 2019 - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its latest advancement in combating antimicrobial resistance (AMR) with new analytics integrated into the company's connected medication management platform that identifies when an inappropriate and potentially ineffective antibiotic has been prescribed, based on a patient's specific infection diagnosis.

There is a heightened focus on antimicrobial stewardship across the health care industry with new reimbursement standards released by Centers for Medicare & Medicaid Services (CMS) requiring hospitals to comply with certain infection prevention and antimicrobial stewardship requirements. 1,2 Additionally, the Centers for Disease Control and Prevention (CDC) released its updated ' Threat Report ' - noting antibiotic-resistant bacteria and fungi cause more than 2.8 million infections and 35,000 deaths in the United States each year.3 Despite public transparency, heightened awareness and financial penalties, hospitals continue to struggle with the burden of health care associated infections (HAIs) and AMR. To help combat these challenges, BD will unveil new antimicrobial stewardship functionality within the BD HealthSight™ connected medication management platform at this year's American Society of Health-System Pharmacists (ASHP) Midyear Meeting being held in Las Vegas from Dec. 9-11.

BD HealthSight Clinical Advisor is a new functionality within the BD HealthSight connected medication management platform that aggregates disparate patient data to provide clinicians with the ability to receive near real-time medication stewardship alerts within the pharmacy workflow. These actionable alerts are delivered within the connected medication management process to help health care providers prevent not only the administration of inappropriate antibiotics, but also the potential waste of resources associated with compounding and preparing unnecessary medication for delivery. Clinical stewardship programs are also supported through customized dashboards, robust reports and the ability to automate the submission of antimicrobial utilization data for regulatory reporting.

'BD is uniquely positioned to deliver some of the most innovative strategies to address the systemic issues associated with medication management,' said Ranjeet Banerjee, worldwide president of Medication Management Solutions for BD. 'We continue to develop actionable solutions to complex health issues that require a multifaceted approach, such as AMR and hospital drug diversion. Our latest advancement in antimicrobial stewardship is a fundamental example of our dedication to help health care workers improve patient outcomes.'

Since introducing the BD HealthSight platform in 2017, BD has expanded and strengthened its offerings of connected technologies, advanced analytics and expert services. This approach includes centralized enterprise-wide analytics, powered by artificial intelligence (AI) in specific use cases, across BD products and connectivity between BD Pyxis and BD Alaris technologies, in addition to connectivity into the electronic medical record (EMR). Added capabilities such as antimicrobial stewardship surveillance and analytics are the result of this truly integrated system, designed with the clinician in mind to help improve efficiencies and outcomes - with the goal of affording more time for health care workers to focus on patient care.

'One of the key weapons in the fight against the growing problem of drug resistant bacteria is effective antimicrobial stewardship in hospitals. Using available antimicrobials appropriately is the only way to maintain their effectiveness long term and avoid collateral damage, which in turn has the ability to help reduce healthcare associated infections,' said Dr. Fares Khater, system director of infectious diseases at Appalachian Regional Healthcare Corporation. 'The ability to have near real-time visibility into medication stewardship alerts will enable our staff to make more informed decisions quickly that have the potential to improve patient outcomes by avoiding specific antibiotics when appropriate.'

BD's AMR strategy addresses the need for a multifaceted approach to curbing the threat of AMR, including the immediate need for advancement in infection prevention and control practices, diagnostics and surveillance tools. BD engages in extensive cross-sector collaboration with leading health agencies, foundations and other organizations around the world to deploy training initiatives, information systems and medical technology that support programs in hospitals and laboratories, tailoring its approach to the stage of development and level of sophistication in each country's efforts to combat AMR. These new integrated capabilities in the BD HealthSight™ platform are the latest in BD infection surveillance technology. Other BD infection surveillance offerings include data mining technology that creates an early warning system to detect infection anomalies before an outbreak occurs and tools for health care facilities to easily report infection data electronically to public health authorities for enhanced monitoring to identify local, regional and national trends.

BD invites conference attendees to visit booth #1637 to learn more about scaling medication management to the enterprise level with a comprehensive approach that links hospitals' technologies, workflows, inventory and clinical decisions involved in medication therapies across the care continuum. For a complete list of exclusive BD in-booth speaking sessions, symposia sponsorships and other conference activities, please visit bd.com/ASHP2019 and follow BD on Twitter @BDandCo for live conference updates.

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Disclaimer

BD - Becton, Dickinson and Company published this content on 21 November 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 November 2019 14:05:00 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BECTON, DICKINSON AND COMP
01/16Health Executives Gear Up for Change at J.P. Morgan Conference
DJ
01/10BECTON DICKINSON AND : LongueVue Capital Adds Experienced Healthcare Operating P..
PR
01/09BECTON DICKINSON AND : BD Announces Live Webcast Of First Fiscal Quarter Earning..
PR
01/06BECTON, DICKINSON AND COMPANY : Report
CO
01/03BECTON DICKINSON AND : BD to Present at the 38th Annual J.P. Morgan Healthcare C..
PR
01/03BECTON, DICKINSON AND COMPANY : Report
CO
2019BECTON, DICKINSON AND COMPANY : Report
CO
2019BECTON, DICKINSON AND COMPANY : Report
CO
2019BECTON, DICKINSON AND COMPANY : Report
CO
2019BECTON, DICKINSON AND COMPANY : Report
CO
More news
Financials (USD)
Sales 2020 18 038 M
EBIT 2020 4 805 M
Net income 2020 2 435 M
Debt 2020 15 093 M
Yield 2020 1,28%
P/E ratio 2020 27,9x
P/E ratio 2021 23,9x
EV / Sales2020 5,00x
EV / Sales2021 4,61x
Capitalization 75 035 M
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Average target price 285,35  $
Last Close Price 276,87  $
Spread / Highest target 13,8%
Spread / Average Target 3,06%
Spread / Lowest Target -7,90%
EPS Revisions
Managers
NameTitle
Vincent A. Forlenza Chairman & Chief Executive Officer
Thomas E. Polen President & Chief Operating Officer
Christopher R. Reidy Chief Financial Officer, CAO & EVP-Administration
John A. DeFord Chief Technology Officer & Executive VP
William R. Sigmund Chief Medical Officer & EVP
Sector and Competitors